Abbott Laboratories (ABT) Cash & Current Investments (2009 - 2026)

Abbott Laboratories has disclosed Cash & Current Investments across 18 years of filings, most recently posting $5.6 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments fell 23.06% year-over-year to $5.6 billion; the TTM figure through Jun 2026 stood at $5.6 billion (down 23.06% YoY), while the FY2025 annual figure was $8.9 billion, up 12.2% from the prior year.
• Cash & Current Investments came in at $5.6 billion for Q2 2026 at Abbott Laboratories, down from $7.3 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $10.2 billion in Q4 2022 to a low of $5.6 billion in Q2 2026.
• Average Cash & Current Investments over 5 years is $7.9 billion, with a median of $7.8 billion recorded in 2024.
• Year-over-year, Cash & Current Investments advanced 16.84% in 2023 and sank 30.22% in 2024.
• Over 5 years, Cash & Current Investments stood at $10.2 billion in 2022, then declined by 28.43% to $7.3 billion in 2023, then gained by 9.45% to $8.0 billion in 2024, then increased by 12.2% to $8.9 billion in 2025, then sank by 37.32% to $5.6 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $5.6 billion in Q2 2026, $7.3 billion in Q1 2026, and $8.9 billion in Q4 2025.